Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.63 | $2,680 | -$2M |
| 2025 Q4 | -0.80 | $3,555 | -$1M |
| 2025 Q3 | -0.98 | $2,855 | -$2M |
| 2025 Q2 | -0.97 | $7,475 | -$2M |
| 2025 Q1 | -0.97 | $940 | -$1M |
| 2024 Q4 | -0.06 | $4,512 | -$1M |
| 2024 Q3 |
| -1.73 |
| $6,580 |
| -$1M |
| 2024 Q2 | -1.71 | $7,870 | -$1M |